Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017, 161(1):31-40 | DOI: 10.5507/bp.2017.002

Adipokines and cardiovascular disease: A comprehensive review

Ales Smekala, Jan Vaclavika
a Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic

Adipokines are peptides that signal the functional status of adipose tissue to the brain and other target organs. In adipose tissue dysfunction, adipokine secretion is altered, and this can contribute to a spectrum of obesity-associated conditions including cardiovascular disease. Some adipokines have anti-inflammatory and cardioprotective effects (omentin, apelin, adiponectin). Others are pro-inflammatory with negative impact on cardiovascular function (leptin, visfatin, resistin, adipocyte fatty-acid-binding protein). In the first part, this article reviews the endocrine functions of adipose tissue in general, effects of the distribution and composition of fat tissue, and the roles of cortisol and the renin-angiotensin-aldosterone system in the development of the inflammatory state of addipose tissue. In the second part, the known cardiovascular effects of different adipokines and their clinical potential are discussed in detail.

Keywords: adipokines, obesity, adipose tissue, cardiovascular effects, myocardial infarction, heart failure, omentin, apelin, adiponectin, leptin, visfatin, resistin, adipocyte fatty-acid-binding protein

Received: August 7, 2016; Accepted: January 26, 2017; Prepublished online: February 16, 2017; Published: March 27, 2017  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Smekal, A., & Vaclavik, J. (2017). Adipokines and cardiovascular disease: A comprehensive review. Biomedical papers, 161(1), 31-40. doi: 10.5507/bp.2017.002
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gualillo O, González-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007;17:275-83. Go to original source... Go to PubMed...
    2. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, Rudich S, Weintraub NL. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 2009;104:541-9. Go to original source... Go to PubMed...
    3. Takaoka M, Nagata D, Kihara S, Shimomura I, Kimura Y, Tabata Y, Saito Y, Nagai R, Sata M. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 2009;105:906-11. Go to original source... Go to PubMed...
    4. Szasz T, Bomfim GF, Webb RC. The influence of perivascular adipose tissue on vascular homeostasis. Vasc Health Risk Manag 2013;9:105-16. Go to original source... Go to PubMed...
    5. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, Lee RM. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiov Res 2006;71(2):363-73. Go to original source... Go to PubMed...
    6. Okura K, Maeno K, Okura S, Takemori H, Toya D, Tanaka N, Miyayama S. Pericardial fat volume is an independent risk factor for the severity of coronary artery disease in patients with preserved ejection fraction. J Cardiol 2015;65(1):37-41. Go to original source... Go to PubMed...
    7. Mahabadi AA, Lehmann N, Kälsch H, Robens T, Bauer M, Dykun I, Budde T, Moebus S, Jöckel KH, Erbel R, Möhlenkamp S. Association of epicar dial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. JACC Cardiovasc Imaging 2014;7(9):909-16. Go to original source... Go to PubMed...
    8. Hirata Y, Tabata M, Kurobe H, Motoki T, Akaike M, Nishio C, Higashida M, Mikasa H, Nakaya Y, Takanashi S, Igarashi T, Kitagawa T, Sata M. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 2011;58:248-55. Go to original source... Go to PubMed...
    9. Yamada H, Sata M. The role of pericardial fat: The good, the bad and the ugly. J Cardiol 2015;65(1):2-4. Go to original source... Go to PubMed...
    10. Iacobellis G, Singh N, Wharton S, Sharma AM. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity (Silver Spring) 2008;16:1693-7. Go to original source... Go to PubMed...
    11. Kim MK, Tomita T, Kim MJ, Sasai H, Maeda S, Tanaka K. Aerobic exercise training reduces epicardial fat in obese men. J Appl Physiol 2009;106:5-11. Go to original source... Go to PubMed...
    12. Park JH, Park YS, Kim YJ, Lee IS, Kim JH, Lee JH, Choi SW, Jeong JO, Seong IW. Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. J Cardiovasc Ultrasound 2010;18:121-6. Go to original source... Go to PubMed...
    13. Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest 2012;42:1287-94. Go to original source... Go to PubMed...
    14. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003;11(2):304-10. Go to original source... Go to PubMed...
    15. Iacobellis G, Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003;88(11):5163-8. Go to original source... Go to PubMed...
    16. Haluzík M, Trachta P, Haluzíková D. Adipose tissue hormones. Vnitr Lek 2010;56(10):1028-34. Go to PubMed...
    17. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35(6),1270-7. Go to original source... Go to PubMed...
    18. Fallo F, Federspil G, Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Current Diabetes Reports 2008;8(1):42-7. Go to original source... Go to PubMed...
    19. Stiefel P, Vallejo-Vaz AJ, García Morillo S, Villar J. Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011;2011:685238. doi:10.4061/2011/685238 Go to original source... Go to PubMed...
    20. Turer AT, Hill JA, Elmquist JK, Scherer PE. Adipose tissue biology and cardiomyopathy: translational implications. Circ Res 2012;111(12):1565-77. Go to original source... Go to PubMed...
    21. Oral EA, EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346(8):570-8. Go to original source... Go to PubMed...
    22. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumié A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-7. Go to original source... Go to PubMed...
    23. Zhang L, Keung W, Samokhvalov V, Wang W, Lopaschuk GD. Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim Biophys Acta 2010;1801:1-22. Go to original source... Go to PubMed...
    24. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801:311-319. Go to original source... Go to PubMed...
    25. Zhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, Clawson DK, DiMarchi RD, Furman TC, Hale JE, Hsiung HM, Schoner BE, Smith DP, Zhang XY, Wery JP, Schevitz RW. Crystal structure of the obese protein leptin-E100. Nature 1997;387(6629):206-9. Go to original source... Go to PubMed...
    26. Enriori PJ, Evans AE, Sinnayah P, Cowley MA. Leptin resistance and obesity. Obesity (Silver Spring) 2006;Suppl 5:254S-258S. Go to original source... Go to PubMed...
    27. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382(6588):250-2. Go to original source... Go to PubMed...
    28. Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, Brinkoetter MT, Gong H, Arampatzi K, Mantzoros CS. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A 2011;108(16):6585-90. Go to original source... Go to PubMed...
    29. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999;282(16):1568-75. Go to original source... Go to PubMed...
    30. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 2002;87:2391-4. Go to original source... Go to PubMed...
    31.  Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110(8):1093-103. Go to original source... Go to PubMed...
    32. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiov Res 2008;79:279-86. Go to original source... Go to PubMed...
    33. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol 2013;216(1);T17-36. Go to original source... Go to PubMed...
    34. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998;31;409-14. Go to original source... Go to PubMed...
    35. Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, Ebihara K, Masuzaki H, Hosoda K, Yoshimasa Y, Nakao K. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes 1999;48(9):1787-93. Go to original source... Go to PubMed...
    36. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R, Somers VK. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol 2007;100(2):234-9. Go to original source... Go to PubMed...
    37. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91(1):295-9. Go to original source... Go to PubMed...
    38. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27(6):515-27. Go to original source... Go to PubMed...
    39. Lu LF, Wang CP, Yu TH, Hung WC, Chiu CA, Chung FM, Tsai IT, Yang CY, Cheng YA, Lee YJ, Yeh LR. Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction. Cytokine 2012;57(1):74-80. Go to original source... Go to PubMed...
    40. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010;8:12-28. Go to original source... Go to PubMed...
    41. Romacho T, Sanchez-Ferrer CF, Peiro C, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013;2013:946427. doi: 10.1155/2013/946427. Go to original source... Go to PubMed...
    42. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clinical Science 2005;109:243-6. Go to original source... Go to PubMed...
    43. Scotece M, Conde J, Gómez R, López V, Pino J, González A, Lago F, Gómez-Reino JJ, Gualillo O. Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediators Inflamm 2012;2012:125458. Go to original source... Go to PubMed...
    44. Savage DG, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50(10):2199-202. Go to original source... Go to PubMed...
    45. Li S, Xu RX, Zhang Y, Guo YL, Zhu GC, Liu G, Dong Q, Li JJ. Relation of resistin to PCSK9 levels in CAD patients with varying degree of obesity. Eur Heart J 2015;36(abstract supplement):923.
    46. Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, Watanabe T, Takabatake N, Kubota I. Serum resistin is associated with high risk in patients with congestive heart failure-a novel link between metabolic signals and heart failure. Circ J 2007;71:460-4. Go to original source... Go to PubMed...
    47. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52(3):405-13. Go to original source... Go to PubMed...
    48. Eynatten MV, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease: A 10-year Prospective Study. Arterioscl Thromb Vasc Biol 2012;32(9):2327-35. Go to original source... Go to PubMed...
    49. Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, Cizek L, Horakova D, Yahia RB, Lichnovska R, Janout V. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest 2007;37(8):637-42. Go to original source... Go to PubMed...
    50. Sovova E, Hobzova M, Stejskal D, Sova M, Kolek V, Zapletalova J. Treatment of obstructive sleep apnea with continuous positive airway pressure decreases adipocyte fatty acid-binding protein levels. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156(1):58-62. Go to original source... Go to PubMed...
    51. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290(6):E1253-61. Go to original source... Go to PubMed...
    52. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655-61. Go to original source... Go to PubMed...
    53. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011;219(2):811-4. Go to original source... Go to PubMed...
    54. Narumi T, Watanabe T, Kadowaki S, Kinoshita D, Yokoyama M, Honda Y, Kubota I. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol 2014;13:84. doi:10.1186/1475-2840-13-84 Go to original source... Go to PubMed...
    55. O'Dowd BF, O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993;136(1-2):355-60. Go to original source... Go to PubMed...
    56. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251(2):471-6. Go to original source... Go to PubMed...
    57. Chandrasekaran B, Dar O, McDonagh T. The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail 2008;10(8):725-32. Go to original source... Go to PubMed...
    58. Hijazi Z, Oldgren J, Siegbahn A, Granger CB,Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013;34:1475-80. Go to original source... Go to PubMed...
    59. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Goudis CA, Maliaraki NE, Saloustros IG, Milathianaki ME, Chlouverakis GI, Vardas PE. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation. Am J Cardiol 2010;105:90-4. Go to original source... Go to PubMed...
    60. Falcone C, Buzzi MP, D'Angelo A, Schirinzi S, Falcone R, Rordorf R, Capettini AC, Landolina M, Storti C, Pelissero G. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. Int J Immunopathol Pharmacol 2010;23:917-25. Go to original source... Go to PubMed...
    61. Tycinska AM, Sobkowicz B, Mroczko B, Sawicki R, Musial WJ, Dobrzycki S, Waszkiewicz E, Knapp MA, Szmitkowski M. The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction. Clin Chim Acta 2010;411:2014-8. Go to original source... Go to PubMed...
    62. Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S, Małyszko J. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels 2010;25:363-7. Go to original source... Go to PubMed...
    63. Kadoglou NP, Lampropoulos S, Kapelouzou A, Gkontopoulos A, Theofilogiannakos EK, Fotiadis G, Kottas G. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease - KOZANI STUDY. Transl Res 2010;155:238-46. Go to original source... Go to PubMed...
    64. Kleinz MJ, Baxter GF. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept 2008;146:271-7. Go to original source... Go to PubMed...
    65. Földes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, Mäyränpää M, Sármán B, Seres L, Skoumal R, Lakó-Futó Z, deChâtel R, Ruskoaho H, Tóth M. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003;308(3):480-5. Go to original source... Go to PubMed...
    66. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients withchronic heart failure. Eur J Heart Fail 2006;8:355-60. Go to original source... Go to PubMed...
    67. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, Ben-Dor A, Fenster B, Yang E, King JY, Fowler M, Robbins R, Johnson FL, Bruhn L, McDonagh T, Dargie H, Yakhini Z, Tsao PS, Quertermous T. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003;108(12):1432-9. Go to original source... Go to PubMed...
    68. Andersen CU, Hilberg O, Mellemkjær S, Nielsen-Kudsk JE, Simonsen U. Apelin and pulmonary hypertension. Pulmon Circ 2013;1(3):334-46. Go to original source... Go to PubMed...
    69. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ regulates cardiac contractility. Circ Res 2002;91:434. Go to original source... Go to PubMed...
    70. Japp AG, Cruden NL, Barnes G, van GN, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newby DE. Acute cardiovascular effects of apelin in humans: Potential role in patients with chronic heart failure. Circulation 2010;121:1818-27. Go to original source... Go to PubMed...
    71. Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, Veitch S, Jeong H, White A, Cruden NL, Huson L, Japp AG, Newby DE. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail 2013;6(3):482-91. Go to original source... Go to PubMed...
    72. Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE, Smith LH. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens 2011;29(4):724-31. Go to original source... Go to PubMed...
    73. Zhang Z, Yu B, Tao GZ. Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin Med J (Engl) 2009;122:2360. Go to PubMed...
    74. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V, Zamanian RT, Quertermous T, Chun HJ. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2011;31(4):814-20. Go to original source... Go to PubMed...
    75. Papadopoulos DP, Mourouzis I, Faselis C, Perrea D, Makris T, Tsioufis C, Papademetriou V. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) 2013;15(5):333-6. Go to original source... Go to PubMed...
    76. Akcilar R, Turgut S, Caner V, Akcilar A, Ayada C, Elmas L, Ozcan TÖ. Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. Clin Exp Hypertens 2013;35(7):550-7. Go to original source... Go to PubMed...
    77. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86(5):1930-5. Go to original source... Go to PubMed...
    78. Hotta K, Funahashi T, Arita Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20(6):1595-9. Go to original source... Go to PubMed...
    79. Kumada M, Kihara S, Sumitsuji S. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23(1):85-9. Go to original source... Go to PubMed...
    80. Azizi Ghanbari A, Dörr R, Spitzer S, Stumpf J, Britz A, Amann-Zalan I, Lodwig V, Ulm B, Schnell O, Lohmann T. Adiponectin in coronary heart disease and newly diagnosed impaired glucose tolerance. Diab Vasc Dis Res 2013;10(5):452-8. Go to original source... Go to PubMed...
    81. Wu Z, Cheng Y, Aung LH, Li B. Association between adiponectin concentrations and cardiovascular disease in diabetic patients: a systematic review and meta-analysis. PLoS One 2013;8(11):e78485. Go to original source... Go to PubMed...
    82. Hao G, Li W, Guo R, Yang JG, Wang Y, Tian Y, Liu MY, Peng YG, Wang ZW. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis 2013;228(1):29-35. Go to original source... Go to PubMed...
    83. Kanhai DA, Kranendonk ME, Uiterwaal CS, van der Graaf Y, Kappelle LJ, Visseren FL. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev 2013;14(7):555-67. Go to original source... Go to PubMed...
    84. Zhang BC, Liu WJ, Che WL, Xu YW. Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case-control studies. Clin Endocrinol (Oxf) 2012;77:370-8. Go to original source... Go to PubMed...
    85. Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, Gu D. Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci 2013;345(6):455-61. Go to original source... Go to PubMed...
    86. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010;120(12),4342-52. Go to original source... Go to PubMed...
    87. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens) 2012;11(1):8-20. Go to original source... Go to PubMed...
    88. El-Menyar A, Rizk N, Al Nabti AD, Hassira SA, Singh R, Abdel Rahman MO, Suwaidi JA. Total and high molecular weight adiponectin in patients with coronary artery disease. J Cardiovasc Med (Hagerstown) 2009;10(4):310-5. Go to original source... Go to PubMed...
    89. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007;49(6):1455-61. Go to original source... Go to PubMed...
    90. Hass A, Oz H, Mashavi M, Shargorodsky M. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients. J Am Soc Hypertens 2014;8(10):709-14. Go to original source... Go to PubMed...
    91. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42(1):76-81. Go to original source... Go to PubMed...
    92. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Martinet W, Van Hoof V, Vrints CJ, Ventura-Clapier R, Conraads VM. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 2010;3(2):185-94. Go to original source... Go to PubMed...
    93. Tanaka T, Tsutamoto T, Sakai H, Nishiyama K, Fujii M, Yamamoto T, Horie M. Effect of atrial natriuretic peptide on adiponectin in patients with heart failure. Eur J Heart Fail 2008;10:360-6. Go to original source... Go to PubMed...
    94. Wang Y, Gao E, Lau WB, Wang Y, Liu G, Li JJ, Wang X, Yuan Y, Koch WJ, Ma XL. G-protein-coupled receptor kinase 2-mediated desensitization of adiponectin receptor 1 in failing heart. Circulation 2015;131(16):1392-404. Go to original source... Go to PubMed...
    95. Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl 2003;84:S98-102. Go to original source...
    96. Cheng P, Zhang F, Yu L, Lin X, He L, Li X, Lu X, Yan X, Tan Y, Zhang C. Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases. J Diabetes Res 2016;2016:1540267. doi: 10.1155/2016/1540267 Go to original source... Go to PubMed...
    97. Planavila A, Redondo-Angulo I, Villarroya F. FGF21 and Cardiac Physiopathology. Front Endocrinol (Lausanne) 2015;6:133. doi: 10.3389/fendo.2015.00133 Go to original source... Go to PubMed...
    98. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD,Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282(38):28175-88. Go to original source... Go to PubMed...
    99. Maghsoudi Z, Kelishadi R, Hosseinzadeh-Attar MJ. The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents. Diabetes Metab Syndr 2016;10(2 Suppl 1):S43-6. Go to original source... Go to PubMed...
    100. Neves KB, Lobato NS, Lopes RA, Filgueira FP, Zanotto CZ, Oliveira AM, Tostes RC. Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity? Clin Sci (Lond) 2014;127(2):111-22. Go to original source... Go to PubMed...
    101. Ji Q, Lin Y, Liang Z, Yu K, Liu Y, Fang Z, Liu L, Shi Y, Zeng Q, Chang C, Chai M, Zhou Y. Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris. Cardiovasc Diabetol 2014;13:145. Go to original source... Go to PubMed...
    102. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359(18):1897-908. Go to original source... Go to PubMed...
    103. Zimmermann O, Li K, Zaczkiewicz M, Graf M, Liu Z, Torzewski J. C-reactive protein in human atherogenesis: facts and fiction. Mediators Inflamm 2014;2014:561428. Go to original source... Go to PubMed...
    104. Wan K, Zhao J, Deng Y, Chen X, Zhang Q, Zeng Z, Zhang L, Chen Y. A genetic polymorphism in RBP4 is associated with coronary artery disease. Int J Mol Sci 2014;15(12):22309-19. Go to original source... Go to PubMed...
    105. Feng R, Li Y, Wang C, Luo C, Liu L, Chuo F, Li Q, Sun C. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract 2014;106(1):88-94. Go to original source... Go to PubMed...
    106. Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 2012;41(2):176-82. Go to original source... Go to PubMed...
    107. Hao F, Zhang H, Zhu J, Kuang H, Yu Q, Bai M, Mu J. Association between vaspin level and coronary artery disease in patients with type 2 diabetes. Diabetes Res Clin Pract 2016;113:26-32. Go to original source... Go to PubMed...

    Return to the content